Iravani Shahrokh, Dooghaie-Moghadam Arash, Razavi-Khorasani Niloofar, Moazzami Bobak, Dowlati Beirami Amirreza, Mansour-Ghanaei Alireza, Majidzadeh-A Keivan, Mehrvar Azim, Khoshdel Alireza, Nasiri Toosi Mohssen, Sadeghi Amir
Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran.
Gastroenterology and Hepatobiliary Research Center, AJA University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):115-124.
Primary sclerosing cholangitis is a chronic cholestatic liver disease defined by strictures of the biliary tree which could ultimately lead to liver cirrhosis and cholangiocarcinoma. Although the exact underlying etiology of this disorder is not fully understood, the pathology is believed to be caused by immune mediated mechanisms. Growing body of evidence suggests several treatment modalities mainly focusing on the inflammation aspect of this disorder. However, there is still no consensus regarding the best treatment option for these patients. Thus, the present study aimed to review the current treatment options for patients with primary sclerosing cholangitis.
原发性硬化性胆管炎是一种慢性胆汁淤积性肝病，其特征为胆管树狭窄，最终可导致肝硬化和胆管癌。尽管这种疾病的确切潜在病因尚未完全明确，但据信其病理是由免疫介导机制引起的。越来越多的证据表明有几种治疗方式主要针对该疾病的炎症方面。然而，对于这些患者的最佳治疗方案仍未达成共识。因此，本研究旨在综述原发性硬化性胆管炎患者目前的治疗选择。
